drugset / Trial / NCT00127504
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
Phase 2
Completed
80 enrolled
Centers for Disease Control and Prevention
Universidad del Valle, Guatemala · collabUniversity of Alabama at Birmingham · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
Timeline
- Start
- 2003-07
- Primary completion
- —
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 12 mg/kg | Oral |
| Subject | Rifampin | Small molecule | 20 mg/kg | Oral |